KeyBanc downgrades Evolent Health stock rating on leverage concerns
#Evolent Health #KeyBanc #Stock Downgrade #Leverage Concerns #Healthcare Technology #EBITDA #Analyst Ratings
📌 Key Takeaways
- KeyBanc downgraded Evolent Health stock rating from Overweight to Sector Weight on leverage concerns
- The stock has declined 76% over the past year, trading near its 52-week low
- While fourth-quarter results beat expectations, 2026 guidance fell short of Wall Street estimates
- Debt leverage is expected to increase to approximately 7 times before potentially moderating in late 2026
📖 Full Retelling
KeyBanc downgraded Evolent Health (NYSE:EVH) to Sector Weight from Overweight on February 25, 2026, following the company's fourth-quarter results and 2026 guidance that revealed leverage concerns. The healthcare technology company's stock, trading at $2.56 near its 52-week low, has declined 76% over the past year despite beating fourth-quarter earnings expectations. The downgrade comes despite Evolent Health delivering fourth-quarter results that exceeded expectations, with EBITDA coming in 6% above estimates and demonstrating steady cost trends across the business. However, the company's 2026 guidance fell short of Wall Street expectations, particularly as it is weighted toward the second half of the year and reflects conservative reserving assumptions for new partnership services contract launches with Aetna and Highmark. KeyBanc had anticipated leverage would begin declining in early 2026, but debt leverage is now expected to increase to approximately 7 times before potentially moderating in late 2026. The downgrade follows significant analyst activity on Evolent Health, with Piper Sandler reducing its price target to $6.00 from $18.00 while maintaining an Overweight rating due to concerns about anticipated enrollment declines in the Individual ACA Marketplace and Medicaid. Citizens also lowered its price target to $10.00 from $11.00, citing more conservative operating margin assumptions for 2026-2027 as the company faces potential erosion of customer ACA membership.
🏷️ Themes
Healthcare Technology, Stock Market Performance, Financial Analysis
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry AMD stock surges 14% on Meta AI partnership deal Bitcoin slips, wipes out 50% from October record high at session low Wall Street ends higher on tech rebound ahead of State of the Union address Software stocks rebound as Anthropic partnerships ease AI disruption fears (South Africa Philippines Nigeria) KeyBanc downgrades Evolent Health stock rating on leverage concerns By Investing.com Analyst Ratings Published 02/25/2026, 01:27 AM KeyBanc downgrades Evolent Health stock rating on leverage concerns 0 EVH -7.58% Investing.com - KeyBanc downgraded Evolent Health (NYSE:EVH) to Sector Weight from Overweight following the company’s fourth-quarter results and 2026 guidance. The stock, currently trading at $2.56, sits near its 52-week low of $2.52 and has declined 76% over the past year. The healthcare technology company delivered fourth-quarter results that beat expectations, with EBITDA coming in 6% above estimates and steady cost trends. The quarter showed solid operational performance across the business. The company’s 2026 guidance fell short of Wall Street expectations and is weighted toward the second half of the year. The guidance reflects conservative reserving assumptions for new partnership services contract launches with Aetna and Highmark. Debt leverage is expected to increase to approximately 7 times before potentially beginning to moderate in late 2026. KeyBanc had anticipated leverage would start declining in early 2026. KeyBanc analyst Matthew Gillmor stated: "We have a deep appreciation for the underlying demand and value prop for EVH’s offerings but feel compelled to move to SW until we gain better visibility into the EBITDA recovery (and leverage reduction)." Despite near-term concerns, InvestingPro analysis suggests the stock is undervalued at current levels, with additional insights available through the platform’s comprehensive Pro Research Report. In other recent news, Evolent Health has been...
Read full article at source